Abstract:Noxious pain signals are transduced in the peripheral nervous system as action potentials, which rely on the activities of voltage-gated sodium channels (NaVs). Blocking NaVs is thus a valuable strategy for pain treatment. Here, we report the characterization of a novel NaVs antagonist, 2-(2-(diethylamino)ethyl)indeno[1,2,3-de]phthalazin-3(2H)-one (C65780), and investigation of its action mechanisms. C65780 inhibited the resting NaV1.7, NaV1.8, and NaV1.9 channels with IC50s of 11.3 ± 0.4 μM, 2.7 ± 0.3 μM and 19.2 ± 2.3 μM, respectively. Mechanistic analysis revealed that C65780 quickly bound to its high-affinity receptor site in NaV1.7 as formed by the fast inactivation process and stabilized the channels in a slowly recovering state, for which it facilitated NaV1.7 channels' inactivation by shifting their inactivation-voltage relationship in the hyperpolarizing direction, increasing the plateau proportion of inactivated channels, and blunting their time-dependent recovery. The slow inactivation of NaV1.7, however, is not involved in the action of C65780. In DRG neurons, C65780 also inhibited activity of NaVs, thus dampening neuronal excitability. These effects parlayed into a broad efficacy of orally administrated C65780 in various models of pain, with an efficacy comparable to the antidepressant/neuropathic pain drug Amitriptyline. Excitingly, C65780 demonstrated weaker inactivated state inhibition of related NaV1.4 and NaV1.5 channels compared to amitriptyline, and no toxicity or inhibition of locomotion in a forced-swimming test was observed in mice at pain-relieving doses. These results demonstrate that C65780 acts by trapping NaVs in the inactivated and slowly-recovering state to produce pain relief and may represent an excellent starting compound for developing analgesics.

Discovery of a novel series of pyridone amides as Na V 1.8 inhibitors

Discovery of a Novel Series of Pyridone Amides As NaV1.8 Inhibitors.

Discovery of selective Na V 1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Identification of N-(((1S,3R,5S)-adamantan-1-yl)methyl)-3-((4-chlorophenyl)sulfonyl)benzenesulfonamide as novel Nav1.8 inhibitor with analgesic profile

Discovery of Selective NaV1.8 Inhibitors Based on 5-Chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl Nicotinamide Scaffold for the Treatment of Pain

2-Aminopyridines as Potent and Selective Na v 1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

Design, Synthesis, and Biological Evaluation of Acyl Sulfonamide Derivatives with Spiro Cycles As NaV1.7 Inhibitors for Antinociception

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Discovery of E0199: A Novel Compound Targeting Both Peripheral NaV and KV7 Channels to Alleviate Neuropathic Pain

Discovery of a novel K V 7.2/7.3 channels agonist for the treatment of neuropathic pain

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

Synthesis and Evaluation of Novel α-Aminoamides Containing Benzoheterocyclic Moiety for the Treatment of Pain

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state

Discovery of Indole- and Indazole-Acylsulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

Synthesis and Biological Evaluation of Novel Σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

Design and Synthesis of Novel Α-Aminoamides Derivatives As Nav1.7 Inhibitors for Antinociception

Novel phenylpiperazine derivatives as potent transient receptor potential vanilloid 1 antagonists

Discovery of 4-(1,2,4-oxadiazol-5-yl)azepan-2-one Derivatives As a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain